Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy (NCT00349830)
Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.
Who can join: Review the eligibility criteria below.
Location: Stanford University School of Medicine — Stanford, California
Age range: 18 Years
🧪 Interventions in This Study
- blood draw (PROCEDURE)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Stanford University School of Medicine — Stanford, California
📞 Contact the Study Coordinator
Phone: (650) 498-7757
Email: gitrialeligibility@stanford.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Carcinomas (Including Squamous Cell and Adenocarcinoma) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.